WuXi AppTec News & Press Releases - Latest Pharmaceutical Industry Updates

Access the latest corporate news and announcements for WuXi AppTec, including business milestones, partner collaborations, quality and regulatory updates, and financial results.
Filter By
All Years

2025/11/19

WuXi AppTec Receives Frost & Sullivan’s 2025 Global Company of the Year Award in the CRDMO Industry

WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been recognized by Frost & Sullivan with the 2025 Global Company of the Year Award in the CRDMO industry. This marks the ninth consecutive year that WuXi AppTec has received this distinguished honor, underscoring the company’s ongoing achievements in enabling innovation and operational excellence for its customers.

Read more

2025/10/28

WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health

Shanghai, October 28, 2025 – WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced it has signed two strategic memoranda of understanding (MoUs) with NEOM, the sustainable region under development in northwest Saudi Arabia and the Ministry of Health of the Kingdom of Saudi Arabia (MOH).

Read more

2025/10/26

WuXi AppTec Signs Definitive Agreement to Sell China-based Clinical Research Services Business to Hillhouse

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, and Hillhouse Investment Management (“Hillhouse”), one of the world’s leading global private alternative asset managers, announced that they have reached an agreement for Hillhouse to acquire WuXi AppTec’s China-based clinical research services business, including WuXi Clinical, a Clinical Contract Research Organization (CRO), and WuXi MedKey, a Site Management Organization (SMO)

Read more

2025/10/26

WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025; Backlog for Continuing Operations Up 41.2% YoY; Further Raises 2025 Full-year Guidance

(SHANGHAI, October 26, 2025) – WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced financial results for the first three quarters ending September 30, 2025 (“Reporting Period”):

Read more

2025/10/26

WuXi AppTec Unveils Modernized Logo, Reflecting Continued Evolution as a Global Healthcare Partner

WuXi AppTec Unveils Modernized Logo, Reflecting Continued Evolution as a Global Healthcare Partner

Read more